Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline
China-based Everest Medicines (HKG: 1952) has announced its 2024 financial results, marking a significant milestone...
HKG: 1952
Everest Medicines’ EVM14 mRNA Cancer Vaccine Clears US FDA IND Application
China-based Everest Medicines (HKG: 1952) has announced that its Investigational New Drug (IND) application for...
Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production
China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in...
Everest Medicines Begins Clinical Trial for Personalized mRNA Cancer Vaccine EVM16
China-based Everest Medicines (HKG: 1952) has announced the first patient dosing of an investigator-initiated clinical...
Everest Medicines’ Nefecon Receives First Prescription for IgAN Treatment in Adults
China-based Everest Medicines (HKG: 1952) has announced that its targeted-release budesonide, Nefecon, has been prescribed...
Everest Medicines’ Velsipity (Etrasimod) Receives First Prescription in Foshan under GBA Policy
Everest Medicines (HKG: 1952), a leading biopharmaceutical company based in China, has announced that its...
Everest Medicines’ Velsipity NDA for Ulcerative Colitis Accepted by China’s NMPA
China-based Everest Medicines (HKG: 1952) has announced that the National Medical Products Administration (NMPA) has...
Everest Medicines’ Nefecon Receives Full Approval from South Korea’s MFDS for IgAN Treatment
China-based Everest Medicines (HKG: 1952) has announced that it has received full approval from the...
Everest Medicines’ Velsipity Approved for Use in Select Hospitals in China’s Greater Bay Area
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received approval...
Everest Medicines’ Nefecon Approved in Taiwan for Primary IgAN Treatment
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received market...
Everest Medicines Reports 158% Revenue Growth in 2024 H1, Driven by Pharmaceutical Sales and Operational Efficiency
Everest Medicines, a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1952),...
Everest Medicines Launches Trial for Personalized mRNA Cancer Vaccine EVM16 in Solid Tumors
Everest Medicines, a biopharmaceutical company based in China and listed on the Hong Kong Stock...
Everest Medicines’ Nefecon Receives NMPA Review, Signaling Potential Treatment Milestone for IgAN Patients
Everest Medicines (HKG: 1952), a biopharmaceutical company dedicated to addressing critical medical needs in Asian...
Everest Medicines’ Velsipity Shows Positive Results in Largest Asian Phase III UC Trial
Everest Medicines (HKG: 1952), a leading biopharmaceutical company based in China, has announced positive top-line...
Everest Medicines Commences Commercial Sales of Nefecon in China Post-Launch
Everest Medicines (HKG: 1952), a leading pharmaceutical company based in China, has announced the official...
Everest Medicines’ Velsipity for UC Receives First Asian Approval in Macau
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that the regulatory authority in...
Everest Medicines’ Nefecon Secures Market Approval for IgAN Treatment in Hong Kong
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, announced that it has received market approval...
Everest Medicines Reports 884% Revenue Surge Amid Rising Losses and Strategic Shifts
Everest Medicines (HKG: 1952), a China-based biotech company, has released its 2023 annual financial results...
Everest Medicines Strengthens Leadership with Appointments of Sandra Zeng and Rico Liang
Everest Medicines (HKG: 1952), a leading China-based biotechnology company, has announced two significant appointments to...
Everest Medicines’ Nefegan Approved by Singapore HSA for Primary IgAN Treatment
Everest Medicines (HKG: 1952), a China-based biotechnology company, has received marketing approval from the Singapore...